Targeting healing of the airway epithelium: more than a buffer between air and smooth muscle
Geography of the beta 2 receptor in the asthmatic airway
The opportunity to facilitate healing of the moderate to severely deranged epithelium
Study design for therapy targeting the airway; signs, symptoms, cells, and biomarkers Dr Mitchell Glass, Executive Vice President R&D & Chief Medical Officer, Invion
Invion's biggest competitor in Lupus is talking about Lupus:
Treatment of Lupus: the physiopathology approach
The sequence: antigen presenting cells, T-cells and B-cells is valid for all auto-immune diseases. Trying to selectively deplete the body from deleterious sub-sets of B-cells led to disappointing results and to an immunosuppressant warning label by regulatory agencies
Targeting of selective auto-reactive T-cells (and therefore sub-sets of B-cells) is possible through the Altered Peptide Ligand approach that allows the modulation of specific sub-sets of T-cells inducing their anergization with consequences toward the respective auto-reactive B-cells.
Additionally, a broader approach involving auto-reactive T-cells and the control of hyperautophagy found in lupus can also lead to their anergization resulting in a depletion of the deleterious auto-reactive B-cells.
Lupuzor a modified 21-mer peptide bearing a T-cell epitope has demonstrated to be able to address both mechanisms with clinically significant results Dr Robert Zimmer, President & Chief Scientific Officer, Immupharma
Kinda shows priorities for Invion !
IVX Price at posting:
4.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)